Loading...
OTCM
HALB
Market cap464kUSD
Jul 09, Last price  
0.00USD
1D
0.00%
1Q
-18.18%
Jan 2017
-35.71%
IPO
-95.50%
Name

Halberd Corp

Chart & Performance

D1W1MN
OTCM:HALB chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
16.00%
Rev. gr., 5y
134.03%
Revenues
0k
7,0157,91533,40180,077297,507200,722228,16087,948164,481151,2250005,2388,0202,72500
Net income
-20k
L-74.81%
-36,095-1,208,000-324,000180,81040,969-211,000-527,000-267,0005,980-373,000-14,228-21,918-1,644,000-861,537-1,624,744-454,072-79,676-20,071
CFO
-52k
L-78.55%
14,901-30100-21,918-42,564-770,299-920,333-240,740-51,636

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Halberd Corporation is a biotechnology firm dedicated to pioneering therapies for neurodegenerative conditions. The company's therapeutic focus encompasses a broad range of serious illnesses, including post-traumatic stress disorder (PTSD) and chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, various forms of cancer, and disorders impacting the blood and cerebrospinal fluid. Established in 2009, Halberd Corporation operates from its headquarters in Jackson Center, Pennsylvania.
IPO date
Jun 12, 2009
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑072024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑07
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT